[ad_1]
NEW YORK, Oct. 14, 2022 /PRNewswire/ — The Insight Partners published latest research study on “Dry Eye Products Market Size, Share, Revenue, Growth Strategy, Industry Trends and Forecast to 2028-COVID-19 Impact Analysis-by Product and Type” the global dry eye products market size is projected to reach USD 9,681.73 million by 2028 from USD 6,837.26 million in 2021; it’s estimated to grow at a CAGR of 5.1% from 2021 to 2028.
Download Sample PDF Brochure of Dry Eye Products Market Size – COVID-19 Impact and Global Analysis with Strategic Insights at: https://www.theinsightpartners.com/sample/TIPRE00012323/
Global Dry Eye Products Market Report Scope, Segmentations, Regional & Country Scope:
|
Report Coverage |
Details |
|
Market Size Value in |
USD 6,837.26 million in 2021 |
|
Market Size Value by |
USD 9,681.73 million by 2028 |
|
growth rate |
CAGR of 5.1% from 2021 to 2028 |
|
Forecast Period |
2021-2028 |
|
Base Year |
2021 |
|
No. of Pages |
154 |
|
No. of Tables |
84 |
|
No. of Charts & Figures |
70 |
|
Historical data available |
Yes |
|
Segments covered |
Product, Type |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Country scope |
US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Companies Covered |
Novartis AG; Santen Pharmaceutical Co., Ltd; Johnson and Johnson Services, Inc; OASIS Medical; URSAPHARM Arzneimittel GmbH; ROHTO Pharmaceutical Co., Ltd; OCuSOFT Inc; Bausch Health Companies Inc; AbbVie Inc; Prestige Consumer Healthcare Inc. |
|
Key Research Capabilities |
Global Market Assessment, Business Development Strategies, Competitive Landscape, Opportunity Analysis, Regional and Country Level Market Analysis, Market Entry Strategies, Market Dynamics, Risk and Return Assessments, Pricing Analysis, Market Size and Forecasting, Company Profiling, Value Chain Analysis, Expansion Strategies , SWOT Analysis, New Product Development |
|
Global Dry Eye Products Market Forecast to 2028 – Latest COVID-19 Analysis |
https://www.theinsightpartners.com/covid-analysis-sample/TIPRE00012323/ |
Browse key market insights spread across 154 pages with 84 list of tables & 70 list of figures from the report, “Dry Eye Products Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product [Antibiotic Drops, Hormone Drops, Artificial Tears (OTC Artificial Tears and Prescription Artificial Tears) and Others] and Type (Prescription Drugs and OTC Drugs)” in detail along with the table of contents: https://www.theinsightpartners.com/reports/dry-eye-products-market
Global Dry Eye Products Market: Competitive Landscape and Key Developments
Novartis AG; Santen Pharmaceutical Co., Ltd; Johnson and Johnson Services, Inc; OASIS Medical; URSAPHARM Arzneimittel GmbH; ROHTO Pharmaceutical Co., Ltd; OCuSOFT Inc; Bausch Health Companies Inc; AbbVie Inc; and Prestige Consumer Healthcare Inc. are among the leading companies operating in the dry eye products market. These players focus on expanding and diversifying their market presence and acquiring a new customer base, thereby exploiting prevailing business opportunities. The overall market is consolidated in nature as the top six to seven players captured the majority portion of dry eye products industry.
In June 2020OCuSOFT Inc. and EKKDA Research, LLC entered into a sales-distribution agreement. This partnership helps the partners to establish and develop in ophthalmology and optometry related business. EKKDA’s research LLC’s projects are focused fundamentally on eye care.
In May 2021URSAPHARM Arzneimittel GmbH has formed a partnership with Scope Eyecare. With the launch of the OPTASE HYLO range of dry eye products in the United States beginning in June 2021the new partnership expands Scope’s Dry Eye Portfolio.
In May 2020AbbVie Inc. acquired Allergan plc as a part of the company’s inorganic business strategy. The acquisition has provided the company access to and expand its business portfolio in the eye care associated markets.
Inquiry Before Purchase:
Full story available on Benzinga.com [ad_2]
Source link
